We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.95%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$61.1B
AUM Growth
+$4.73B
(+8.4%)
Cap. Flow
+$390M
Cap. Flow
% of AUM
0.64%
Top 10 Holdings %
Top 10 Hldgs %
17.66%
Holding
2,331
New
154
Increased
918
Reduced
1,058
Closed
154
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$144M |
| 2 |
Cisco
CSCO
|
+$123M |
| 3 |
Moderna
MRNA
|
+$120M |
| 4 |
JPMorgan Chase
JPM
|
+$95.4M |
| 5 |
FedEx
FDX
|
+$86.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$124M |
| 2 |
Mastercard
MA
|
+$101M |
| 3 |
Home Depot
HD
|
+$95.7M |
| 4 |
Amazon
AMZN
|
+$74.1M |
| 5 |
Eli Lilly
LLY
|
+$72.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.6% |
| 2 | Consumer Discretionary | 14.64% |
| 3 | Healthcare | 14.47% |
| 4 | Industrials | 11.01% |
| 5 | Consumer Staples | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Schrodinger
SDGR
$1.4B
| $756K | ﹤0.01% |
+9,911
| New | +$891K |
|
1677
ANI Pharmaceuticals
ANIP
$1.71B
| $752K | ﹤0.01% |
20,816
-13,424
| -39% | -$420K |
|
|
MRSN
1678
DELISTED
Mersana Therapeutics
MRSN
| $751K | ﹤0.01% |
1,857
+235
| +14% | +$114K |
|
1679
Origin Bancorp
OBK
$1.66B
| $751K | ﹤0.01% |
+17,711
| New | +$622K |
|
1680
3D Systems Corp
DDD
$631M
| $746K | ﹤0.01% |
+27,185
| New | +$899K |
|
1681
Douglas Emmett
DEI
$1.92B
| $746K | ﹤0.01% |
23,771
-96,148
| -80% | -$2.93M |
|
|
RTL
1682
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $743K | ﹤0.01% |
75,643
-35,599
| -32% | -$310K |
|
1683
Kodiak Sciences
KOD
$2.63B
| $739K | ﹤0.01% |
6,514
+2,116
| +48% | +$289K |
|
1684
Adaptive Biotechnologies
ADPT
$4.04B
| $734K | ﹤0.01% |
+18,721
| New | +$1.01M |
|
1685
Seaboard Corp
SEB
$3.99B
| $734K | ﹤0.01% |
+199
| New | +$667K |
|
1686
AtriCure
ATRC
$2.19B
| $733K | ﹤0.01% |
11,184
-7,828
| -41% | -$482K |
|
|
HTBK
1687
DELISTED
Heritage Commerce
HTBK
| $732K | ﹤0.01% |
+59,897
| New | +$599K |
|
1688
NeoGenomics
NEO
$2.12B
| $732K | ﹤0.01% |
15,177
-27,274
| -64% | -$1.42M |
|
1689
Washington Trust Bancorp
WASH
$744M
| $732K | ﹤0.01% |
14,175
-6,753
| -32% | -$327K |
|
1690
IDEAYA Biosciences
IDYA
$3.55B
| $730K | ﹤0.01% |
31,066
-7,893
| -20% | -$152K |
|
|
NAGE
1691
Niagen Bioscience
NAGE
$244M
| $722K | ﹤0.01% |
77,337
-81,559
| -51% | -$646K |
|
1692
LivePerson
LPSN
$33.4M
| $721K | ﹤0.01% |
912
-62
| -6% | -$57.4K |
|
1693
H.B. Fuller
FUL
$3.34B
| $718K | ﹤0.01% |
11,417
+6,819
| +148% | +$388K |
|
|
FOCS
1694
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $718K | ﹤0.01% |
17,250
| – | – |
|
1695
Genco Shipping & Trading
GNK
$1.08B
| $716K | ﹤0.01% |
71,059
+50,417
| +244% | +$486K |
|
|
RDUS
1696
DELISTED
Radius Health, Inc.
RDUS
| $714K | ﹤0.01% |
34,219
-16,256
| -32% | -$343K |
|
1697
Mine Safety
MSA
$7.45B
| $711K | ﹤0.01% |
4,740
-14,706
| -76% | -$2.37M |
|
1698
First Merchants
FRME
$2.69B
| $708K | ﹤0.01% |
15,219
-1,977
| -11% | -$85.2K |
|
1699
LivaNova
LIVN
$4.33B
| $704K | ﹤0.01% |
9,547
-12,720
| -57% | -$908K |
|
1700
Ebang International Holdings
EBON
$13.2M
| $702K | ﹤0.01% |
+2,943
| New | +$630K |
|
Similar funds
VGA
AQR Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, AQR Capital Management held 2,331 positions worth $61.1B, up 8.4% from $56.4B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
AQR Capital Management's Q1 2021 filing shows 154 new, 918 increased, 1,058 reduced and 154 closed positions. Its largest new stake was Janus Henderson: 506,382 shares worth $15.8M. The largest sale was Microsoft, an estimated $124M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- AQR Capital Management's largest Q1 2021 buy was Janus Henderson: 506,382 shares worth $15.8M.
- AQR Capital Management added most to Thermo Fisher Scientific in Q1 2021, an estimated $144M increase.
- AQR Capital Management's biggest Q1 2021 reduction was Microsoft, cutting an estimated $124M.
- AQR Capital Management fully exited State Street SPDR S&P 500 ETF Trust in Q1 2021, selling an estimated $39.7M.
- AQR Capital Management's ten largest holdings make up 18% of its $61.1B portfolio in Q1 2021.
- AQR Capital Management opened 154 new positions and closed 154 in Q1 2021.
- AQR Capital Management's portfolio value rose 8.4% quarter-over-quarter to $61.1B.
Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.